We are live on
!
Find out more
QC
Quadrature Capital Portfolio holdings
AUM
$11.7B
1-Year Est. Return
87.29%
This Fund
S&P 500
This Quarter
Est. Return
+21.58%
1 Year Est. Return
+87.29%
3 Year Est. Return
+211.84%
5 Year Est. Return
+162.22%
10 Year Est. Return
+656.25%
AUM
$5.81B
AUM Growth
+$1.3B
(+29%)
Cap. Flow
+$598M
Cap. Flow
% of AUM
10.3%
Top 10 Holdings %
Top 10 Hldgs %
27.87%
Holding
1,608
New
576
Increased
221
Reduced
201
Closed
609
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$302M |
| 2 |
NVIDIA
NVDA
|
+$270M |
| 3 |
UnitedHealth
UNH
|
+$214M |
| 4 |
Microsoft
MSFT
|
+$134M |
| 5 |
Netflix
NFLX
|
+$101M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Canadian National Railway
CNI
|
+$215M |
| 2 |
Broadcom
AVGO
|
+$213M |
| 3 |
Canadian Natural Resources
CNQ
|
+$109M |
| 4 |
State Street Materials Select Sector SPDR ETF
XLB
|
+$99.2M |
| 5 |
Cenovus Energy
CVE
|
+$85.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.13% |
| 2 | Financials | 14.38% |
| 3 | Healthcare | 11.31% |
| 4 | Communication Services | 7.09% |
| 5 | Consumer Discretionary | 5.59% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
976
Caesarstone
CSTE
$79.5M
| $35.9K | ﹤0.01% |
+18,340
| New | +$41.5K |
|
977
Protara Therapeutics
TARA
$232M
| $35.2K | ﹤0.01% |
+11,591
| New | +$40K |
|
978
Outlook Therapeutics
OTLK
$191M
| $34.8K | ﹤0.01% |
+21,683
| New | +$34.6K |
|
979
TScan Therapeutics
TCRX
$52M
| $32.9K | ﹤0.01% |
+22,500
| New | +$32.5K |
|
|
OLPX
980
DELISTED
Olaplex Holdings
OLPX
| $32.2K | ﹤0.01% |
23,108
-29,189
| -56% | -$38K |
|
|
FSP
981
Franklin Street Properties
FSP
$46.8M
| $30.7K | ﹤0.01% |
+18,620
| New | +$31K |
|
982
Lucid Diagnostics
LUCD
$184M
| $28.7K | ﹤0.01% |
+24,917
| New | +$32.2K |
|
983
Arbe Robotics
ARBE
$94.2M
| $28.6K | ﹤0.01% |
+16,023
| New | +$22.9K |
|
|
NIPG
984
NIP Group Inc
NIPG
$67.4M
| $28.5K | ﹤0.01% |
+393
| New | +$18.9K |
|
985
Werewolf Therapeutics
HOWL
$19.3M
| $28K | ﹤0.01% |
+25,791
| New | +$26.5K |
|
986
Rackspace Technology
RXT
$1.24B
| $26.5K | ﹤0.01% |
+20,605
| New | +$26.8K |
|
987
Acrivon Therapeutics
ACRV
$74M
| $26.3K | ﹤0.01% |
+22,175
| New | +$30.4K |
|
988
MacroGenics
MGNX
$257M
| $25.7K | ﹤0.01% |
+21,105
| New | +$30.6K |
|
989
PSQ Holdings
PSQH
$14.7M
| $22.7K | ﹤0.01% |
+738
| New | +$22.6K |
|
990
Castellum
CTM
$58.3M
| $22.2K | ﹤0.01% |
+21,089
| New | +$21.7K |
|
991
OmniAb
OABI
$447M
| $21.3K | ﹤0.01% |
+12,258
| New | +$20.5K |
|
992
C4 Therapeutics
CCCC
$412M
| $19.3K | ﹤0.01% |
13,547
-2,462
| -15% | -$3.58K |
|
993
Companhia Siderúrgica Nacional
SID
$1.23B
| $16.1K | ﹤0.01% |
+11,542
| New | +$17.8K |
|
994
Village Farms International
VFF
$253M
| $15.9K | ﹤0.01% |
+14,510
| New | +$12.8K |
|
995
Zura Bio
ZURA
$566M
| $15.8K | ﹤0.01% |
+15,158
| New | +$18.1K |
|
996
Cerus
CERS
$474M
| $15.5K | ﹤0.01% |
10,997
-9,203
| -46% | -$12.3K |
|
997
Pyxis Oncology
PYXS
$236M
| $13.6K | ﹤0.01% |
+12,334
| New | +$13.9K |
|
|
RAY
998
Raytech Holding Ltd
RAY
$17.2M
| $13.4K | ﹤0.01% |
+709
| New | +$20.8K |
|
999
GrowGeneration
GRWG
$90.7M
| $9.76K | ﹤0.01% |
+10,353
| New | +$11K |
|
1000
Agilent Technologies
A
$41.2B
| – | – |
-7,396
| Closed | -$865K |
|
Similar funds
BCI
VA
HTC
NYLIM
MIFH
PI
UE
LC
Quadrature Capital's Q2 2025 Portfolio in Review
As of Q2 2025, Quadrature Capital held 1,608 positions worth $5.81B, up 29% from $4.51B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Quadrature Capital deployed $598M of net new capital in Q2 2025, opening 576 new positions and adding to 221 existing holdings. Its largest new stake was Apple: 1,493,459 shares worth $306M.
By sector, the portfolio is most concentrated in Technology at 28% of assets, up from 14% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Canadian National Railway, an estimated $215M trimmed.
- Quadrature Capital's largest Q2 2025 buy was Apple: 1,493,459 shares worth $306M.
- Quadrature Capital added most to UnitedHealth in Q2 2025, an estimated $214M increase.
- Quadrature Capital's biggest Q2 2025 reduction was Canadian National Railway, cutting an estimated $215M.
- Quadrature Capital fully exited Broadcom in Q2 2025, selling an estimated $213M.
- Quadrature Capital's ten largest holdings make up 28% of its $5.81B portfolio in Q2 2025.
- Quadrature Capital opened 576 new positions and closed 609 in Q2 2025.
- Quadrature Capital's portfolio value rose 29% quarter-over-quarter to $5.81B.
Based on Quadrature Capital's 13F filing for Q2 2025, filed 13 Aug 2025.